03-311 Trastzumab preoperative Trial of Early Stage HER2+ BRCA
Ontology highlight
ABSTRACT: Tumor core biopsies were obtained at baseline and after brief-exposure to single-agent trastuzumab from patients enrolled on the 03-311 trial. Gene expression profiling was conducted on these tumor biopsies to identify signatures of response to preoperative therapy. This study was initiated to identify biomarkers of response to preoperative trastuzumab-conotaining therapy. We performed transcriptional profiling of patient tumor biopsies obtained at baseline and post brief-exposure to trastuzumab to test the hypothesis that transcriptional changes upon brief-exposure to therapy can provide an early readout of subsequent response.
ORGANISM(S): Homo sapiens
PROVIDER: GSE76360 | GEO | 2016/02/09
SECONDARY ACCESSION(S): PRJNA307099
REPOSITORIES: GEO
ACCESS DATA